Fig. 1From: Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecanSupervised clustering of 522 kinase genes that are differentially expressed between patients with and without tumor response to CI and between patients with and without the disease control to CI. RR; complete response plus partial response: DCR; RR plus stable diseaseBack to article page